Lenvatinib administration for elderly patients (over 80 years old) with advanced thyroid cancer

Hiroyuki Ozawa, Mariko Sekimizu, Fumihiro Ito, Yuichi Ikari, Nana Nakahara, Shin Saito, Keisuke Yoshihama, Kaoru Ogawa

研究成果: Article査読


When treating advanced thyroid cancer cases with Lenvatinib, most of these patients are old and we sometimes hesitate to administer the drug to elderly cases. We have experienced administering low-dose Lenvatinib to aging patients who were over 80 years old. The first case was a 92-year-old man. He was administered 10mg of Lenvatinib at the outpatient clinic, could continue the treatment without serious side effects, and maintained PR for one year. The second case was an 86-year-old female. She had an obstructed airway due to tumor invasion. Due to her poor general condition, we decided to start with 4 mg of Lenvatinib. The trachea-invading tumor shrank, and she was able to stay at home, but eventually died when the tumor progressed. Low-dose Lenvatinib administration was shown to be tolerated and to reduce side effects even in the elderly. This treatment, however, may have insufficient antitumor effects. The organ function, social status, and living environment of older adults are varied, so we should decide the administration dose and method according to the condition of each case.

ジャーナルJapanese Journal of Head and Neck Cancer
出版ステータスPublished - 2018

ASJC Scopus subject areas

  • 耳鼻咽喉科学
  • 腫瘍学


「Lenvatinib administration for elderly patients (over 80 years old) with advanced thyroid cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。